✨ Onyx Summary Guardant Health launched FPG 360, an in-house liquid biopsy testing service at Policlinico Gemelli in Rome, enabling on-site use of Guardant360 CDx technology for routine care and clinical research within one of Italy’s largest oncology centers. The partnership extends Guardant’s European public-private model by embedding liquid
✨ Onyx Summary Geron presented new ASH 2025 data reinforcing RYTELO (imetelstat) activity in lower-risk MDS and myelofibrosis, including analyses linking early treatment-emergent cytopenias to subsequent hemoglobin gains and transfusion independence in the IMerge program. Updated long-term outcomes from IMerge and biomarker findings from IMbark further support ongoing development of imetelstat
✨ Onyx Summary Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial showing that REC-4881, an investigational allosteric MEK1/2 inhibitor, delivered rapid and durable reductions in polyp burden in patients with familial adenomatous polyposis, with effects persisting after treatment cessation. The results represent the first clinical validation
✨ Onyx Summary Legend Biotech Corporation reported updated ASH 2025 data showing CARVYKTI® achieved a median progression-free survival of 50.4 months in triple-class-exposed multiple myeloma patients with three prior lines of therapy, with translational analyses indicating stronger immune fitness when used earlier in treatment. The company also presented first-in-human Phase
✨ Onyx Summary Lexicon Pharmaceuticals announced that new clinical data from the SOTA-P-CARDIA trial evaluating the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients with HFpEF will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum in December 2025. The presentation adds to prior cardiovascular data on
✨ Onyx Summary Guardant Health will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium (Dec. 9–12, 2025) highlighting data across Guardant Reveal and Guardant360 Liquid that evaluate tissue-free, blood-based testing for minimal residual disease detection, treatment response assessment, relapse risk prediction, and breast cancer subtyping from early-stage
✨ Onyx Summary Perspective Therapeutics announced that updated safety and preliminary efficacy data from its [212Pb]VMT-α-NET program in advanced SSTR2-expressing neuroendocrine tumors have been accepted for presentation at the ASCO Gastrointestinal Cancers Symposium 2026. The accepted abstract builds on previously reported interim results showing a favorable safety profile and early
✨ Onyx Summary VeriSIM Life was named the winner of the AI in Action Award at the Reuters Global Pharma Awards 2025 for its BIOiSIM platform, which applies explainable, mechanistic AI to predict human safety, efficacy, and translational outcomes earlier in drug development. The recognition highlights VeriSIM Life’s growing role
✨ Onyx Summary MassBio and SCbio opened applications for the Spring 2026 cohort of Drive, a national accelerator for early-stage biotech and biomarker/diagnostic startups, with programs running March 23–May 15, 2026 and an application deadline of January 16, 2026. The announcement reflects continued investment in early scientific founders, building
✨ Onyx Summary enGene Holdings Inc. announced that the U.S. Food and Drug Administration has selected its investigational non-viral gene therapy detalimogene voraplasmid for participation in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. The selection supports enGene’s commercial-scale manufacturing strategy and regulatory preparation as
✨ Onyx Summary Alzheon, Inc. announced a peer-reviewed publication in CNS Drugs synthesizing evidence that hippocampal volume on MRI tracks cognitive decline and therapeutic response in early symptomatic Alzheimer’s disease, supporting its use as a surrogate marker in clinical development. The review proposes a hippocampal volume preservation threshold (≥40 mm³
✨ Onyx Summary Belite Bio priced an underwritten public offering of 2,272,727 ADSs at $154.00 per ADS, with a 30-day option for underwriters to purchase up to an additional 340,909 ADSs, for expected gross proceeds of about $350 million before fees and expenses, with closing anticipated around
✨ Onyx Summary Belite Bio commenced an underwritten public offering of ADSs, with all shares sold by the company and an additional 30-day underwriter option for extra ADSs, subject to market conditions. Proceeds are earmarked for commercialization buildout, pipeline development and expansion, and general corporate purposes, with Morgan Stanley, Leerink, BofA
✨ Onyx Summary Belite Bio reported positive topline Phase 3 DRAGON results showing its oral therapy tinlarebant met the primary endpoint in Stargardt disease type 1, delivering a statistically significant 35.7% reduction in retinal lesion growth versus placebo over 24 months in 104 adolescent patients. The company said the safety
✨ Onyx Summary Recursion announced it will host a December 8, 2025 company webinar to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial evaluating REC-4881 monotherapy in patients with familial adenomatous polyposis, including new safety and efficacy data. Salt Lake City, Dec. 01, 2025 – Recursion (Nasdaq:
✨ Onyx Summary Cellares appointed Ali Soleymannezhad as Chief Commercial Officer to lead global commercial strategy as it scales its IDMO Smart Factory network across the U.S., Europe, and Japan, positioning the company for commercial expansion ahead of a potential IPO. The hire underscores Cellares’ strategy to address global cell
